Login to Your Account



Pharma: Clinic Roundup


Monday, September 23, 2013
• Janssen Pharmaceuticals Inc., of Raritan, N.J., part of Johnson & Johnson, said a pooled analysis of the Phase III EINSTEIN program showed Xarelto (rivaroxaban) is as effective as standard of care in reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in people with symptomatic DVT or PE while reducing the incidence of major bleeding by 46 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription